Trump Targets Drugs | Russia Hit | Tesla Drops

It closed under pressure after a sharp swing. 

Oil surged early and set the range. WTI jumped over 10% near $110 before easing slightly.

That move hit risk right at the open. Stocks dropped fast, with the Nasdaq down over 2%. The Dow fell more than 1% at its worst.

Buyers stepped in through the session. Losses narrowed, but didn’t fully reverse. Oil moved first, equities adjusted after.

Yields stayed flat and didn’t support the bounce.

Investor Signal

This closed as a contained pullback. Oil defined the range and capped upside. Buyers returned, but conviction stayed limited. Positioning remains reactive to energy swings.

Most great stocks look boring when the real opportunity begins.

They’re still building scale, executing quietly, and being ignored by most investors.

That’s often when long-term winners are made.

The original market leaders didn’t become obvious overnight.

Our analysts believe the same pattern is forming again.

In These 7 Stocks Will Be Magnificent in 2026, we highlight companies that may look unremarkable today… 

But you’ll soon see they all have the traits that historically define future market leaders.

Get the full list free today.

The pharmaceutical industry woke up to a serious threat today. The Trump administration is planning tariffs of up to 100% on branded drugs from companies that haven't struck pricing deals with the White House. If you haven't sat down with the administration and agreed on terms, your most profitable products could double in cost overnight.

The system works in two tracks. Companies that already have deals, like Lilly, Pfizer, and Novo Nordisk, get three years of protection. Companies still negotiating also get temporary shelter. Everyone else faces the full 100% rate right now.

Here's what else matters:

The companies that moved early are safe. The ones that waited are now in serious trouble. This lands the same week Lilly got FDA approval for its $149 weight loss pill. Lilly has a deal. Its competitors might not.

The Deadline 

This is a forced timeline. Companies without White House deals are now racing to get one before the hammer drops.

Everyone's been watching the Strait of Hormuz since the Iran war started. That's the headline oil story. But there's a second supply shock building quietly that the market hasn't priced yet.

Ukraine has been hitting Russian oil ports in the Baltic Sea with drones for weeks. Russia's export capacity has dropped by roughly 1 million barrels per day. That's about 20% of what Russia normally ships out. The major port Ust-Luga suspended operations last week after drone strikes and fires. Oil is now backing up inside Russia's storage system because it can't get out fast enough.

The IEA already said April's supply loss will be double March's. That estimate only counted Hormuz. Russia's losses weren't fully included. Every analyst modeling oil prices right now is working with an incomplete picture.

The Second Shock 

Two major oil routes are constrained at the same time. The market only priced one. Oil prices haven't caught up to a two-shock reality. That's the repricing still ahead.

The legendary stockpicker who built one of Wall Street’s most popular buying indicators just announced the #1 stock to buy for 2026. 

His last recommendations shot up 100% and 160%. 

Now for a limited time, he’s sharing this new recommendation live on-camera, completely free of charge. It’s not NVDA, AMZN, TSLA, or any stock you’d likely recognize. 

Click here for the name and ticker.

When Microsoft moved Mustafa Suleyman away from leading Copilot recently, investors read it as the AI bet failing. What was actually happening was a deliberate shift toward independence from OpenAI.

Microsoft's original deal with OpenAI had a clause. This prevented Microsoft from building its own advanced AI models. That clause was removed last year. Microsoft is now doing exactly what it was previously blocked from doing. Suleyman wasn't pushed aside. He was moved to lead the effort that actually matters most.

The goal is to build Microsoft's own state-of-the-art AI models across text, images, and audio by 2027. The company started building the computing infrastructure in October and is ramping up over the next 12 to 18 months.

The Long Game 

Azure's $625 billion backlog is the near-term revenue story. Building frontier models is the long-term one. If Microsoft gets there by 2027, its dependence on OpenAI changes fundamentally.

Yesterday Eli Lilly got FDA approval for Foundayo, its new once-daily weight loss pill. Today Novo Nordisk published data attacking it. The timing was deliberate.

Novo's analysis claimed patients on Foundayo were 14 times more likely to stop taking it due to side effects than those on their rival Wegovy pill. A separate survey said 84% of patients preferred Wegovy's profile. Neither study was a direct comparison. Both used existing data from separate trials to make Lilly look worse.

The clinical gap is real too. Wegovy produces 16.6% average body weight loss. Foundayo produces 12.4%. Wegovy also has heart health approval. Foundayo doesn't yet. Lilly's pitch is that its pill has no food restrictions, making it easier to take. Novo's CEO said patients care about results, not convenience.

The Eight-Week Window

Foundayo hasn't filled a single prescription at scale yet and Novo is already on the attack. The next eight weeks of prescription data will show who's winning this argument with doctors.

A crypto supply shock may be forming right now and most investors haven’t noticed.

The GENIUS Act just cleared the way for banks to issue U.S. dollar–backed crypto, while the Trump family’s DeFi platform has applied for a federal bank charter tied to its $3.3B stablecoin.

That could open the door for massive institutional money to finally enter the market.

One small coin sits at the center of this ecosystem with a market cap still under $2B.

Discover the #1 coin positioned for the coming crypto flood.

© 2026 Boardwalk Flock LLC. All Rights Reserved. 2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies. Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

Tesla delivered 358,023 vehicles in the first quarter of 2026. Analysts expected 370,000. The stock dropped about 4%. 

Here's what makes it more interesting. Since the Iran war pushed gas above $4 a gallon, EV inquiries on car-selling platforms jumped 28%. People are suddenly curious about electric vehicles again. But curiosity and purchases are different things. Cox Automotive says gas prices need to stay elevated for at least six months before buying behavior actually shifts.

Tesla is also in an awkward product moment. Model S and X production ended. The Cybertruck never went mainstream. The Cybercab hasn't launched. So 97% of deliveries came from just two models.

Here's the fuller picture:

The Lag 

People are interested in EVs right now. Interest doesn't move the delivery number. The real demand shift, if it comes, is still months away.

Every story today changed shape when the details arrived. Trump's drug tariffs forced a deadline. Russia's oil losses added a shock the market hadn't priced. Microsoft's move was strategy, not failure. Novo attacked Lilly before Foundayo filled a single prescription.

The headline was never the whole read. That's been the week.